ArticleContraception2025
Characteristics of people obtaining mifepristone and misoprostol and misoprostol-only telehealth medication abortion services in the United States.
Article in Contraception, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectivesThis study compares the characteristics of people using mifepristone/misoprostol and misoprostol-only telehealth medication abortion regimens in the United States. STUDY
designWe abstracted and analyzed characteristics for all clients using a virtual clinic between April 27, 2020, and May 31, 2022. We compare sociodemographic characteristics between clients who used either mifepristone and misoprostol or misoprostol only. We conducted multivariable analyses to identify characteristics associated with using each regimen.
resultsThe analytic sample included 8790 clients: 84% used mifepristone and misoprostol, and 16% used misoprostol only. Most clients (54%) were aged 26 to 35 years. Characteristics of having fewer years of education, living in the Mid-Atlantic or Midwest, and reporting a lower income were positively associated with using misoprostol only. Characteristics of identifying as White or a race other than Black or White, as well as having higher levels of education and reporting a higher income, were positively associated with using mifepristone/misoprostol. Although not directly tested, associated characteristics indicate that a difference in regimen price may have influenced regimen use.
conclusionsFindings demonstrate the range of people who have telehealth medication abortions and suggest some differences between clients who used mifepristone/misoprostol and clients who used misoprostol only. IMPLICATIONS: As mifepristone continues to be restricted and telehealth abortions are a growing share of the medication abortions provided in the United States, these findings inform service delivery for clinics considering expanding into telehealth to provide misoprostol-only regimens. Findings also inform expanding policies aimed at the affordability of services, including expanding coverage from private, public, and Medicaid insurance programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.